Emergent Medical Partners is a California-based life sciences investment firm focused on medical device and healthcare companies. The firm was founded in 2006 and is headquartered in Portola Valley, California, United States.

Emergent Medical Partners

HealthCor Partners Management, L.P. (''HealthCor Partners''), is a registered investment advisor with the U.S. Securities and Exchange Commission (the “SEC”). Together with its affiliate, HealthCor Partners has approximately $365 million of capital commitments dedicated to private equity investments. HealthCor Partners invests primarily in growth equity and later stage developmental companies across all sectors of the healthcare and life sciences industry.

HealthCor Partners

U.S. Venture Partners (USVP) is a venture capital partnership, helping entrepreneurs transform their ideas and efforts into world-changing companies. The firm focuses on early-stage ventures in information technology and health care, where innovation is unbridled and has led to the creation of economic wealth and millions of jobs over the past thirty-plus years of the firm's existence.  Areas of particular interest to our investment professionals include enterprise software, IT security, consumer internet, mobile, and e-commerce, healthcare, and IT-enabled healthcare services. The USVP team consists of former entrepreneurs, technologists, corporate executives, financial professionals, and industry domain experts.

U.S. Venture Partners

Capricorn Investment Group was created in 2000 to demonstrate the promise that it is possible to invest profitably while driving sustainable positive change.  Today Capricorn manages the assets for Jeff Skoll, the Skoll Foundation, and others who strive for extraordinary investment results by leveraging market forces to accelerate large-scale impact.  The firm invests in the public equity, fixed income, private equity, and real assets markets across the globe.  Capricorn has offices in Palo Alto, California, and New York, New York.

Capricorn Investment Group

Lifeforce Capital invests in digital health companies enabling new care delivery models or more efficient therapeutic development. Lifeforce Capital is headquartered in San Francisco, California.

Lifeforce Capital

Panorama is a growth private equity firm based in Omaha, with professionals in Palo Alto, Denver, and NYC, having deep roots in Mid-America and Silicon Valley. Over $125M in committed capital from leading family offices, foundations, and entrepreneurs worldwide in Panorama Point Partnership, LP (Fund I), and Co-Investments. Panorama is raising its second investment fund, Panorama Growth Partners, LP (Fund II) – targeting $200M.   Founded on 25 years of investment experience by Stephen J. George, who was previously the Co-Founder and CIO of Capricorn Investment Group, a $5B private investment firm; and Clarey L. Castner, the former CEO of the University of Nebraska Foundation.  Commenced operations in 2013 with the mission to be the most dynamic and rewarding private equity partnership worldwide. At the core of Panorama’s investment philosophy is to invest in compelling, hard-to-access diversified growth-stage companies across the risk-reward spectrum.

Panorama Point Partners

Wellington Management focuses on investment management. The company applies its full resources to meet the needs of the institutional clients they serve. Their investment approaches span equity, fixed income, currency, commodity, and alternative markets. They also offer asset allocation, multi-manager, and speciality approaches.

Wellington Management

Baillie Gifford is an independently owned investment management firm. It is owned and run by 39 of its senior executives, who operate as a partnership, a structure that has endured for over a century and provides stability for clients and motivation for employees. It enables them to manage the business for the future as well as the present, with an emphasis on genuine long-term thinking rather than lurching haplessly between short-term targets.

Baillie Gifford

Cube is the family office founded by the Rancilio family in 2013, after the sale of the espresso machine company founded in 1927 by our grandfather Roberto. The Rancilio family managed its company for three generations, during the course of which it became a leading global espresso producer. After selling the family business, we created Rancilio Cube. Cube focuses on venture, growth and impact investments, and makes both direct and fund investments. With regard to direct investments, we invested in companies such as Lyft (made in 2015, we consider it as our ''cornerstone'' venture/growth investment), Sennder, N26, SpaceX, Airbnb, Wise, 23andme, Uber, Flexport, Deliveroo, SumUp, Capsule, Coursera, Lyst, Omaze, Prodigy Finance, Taboola, Applause, Reef, Rapyd, Logz.io, Tier, Toast, Bnext, Treedom, Casavo and many more.  Cube also makes limited partner investments in international VC funds: examples include Pelion, Earlybird DE, Cherry Venture, Foundation Capital, Khosla, NEA, Lake Star, Hoxton Venture, Hetz, Glilot, Cavalry, Bessemer, Omega, Blue Lion, TCV, Firstmark, Seedcamp, Holtzbrinck, OWL, Better Tomorrow, Zetta, DST, Jackson Square Venture, GSquared, Speedinvest, Target GlobaI, Aspect Ventures, Oxford Science Innovation, Triodos Organic Growth and other funds. From 2022 we are a fully compliant investment company for professional investors. We got an embedded global network, with a particularly deep and wide set of relationships in the Us/European investment and corporate markets. Cube goes out of its way to open up its networks for the benefit of the companies and funds in which it has invested.

Rancilio Cube Sicaf

Martis Capital is a middle-market private equity fund focused exclusively on the North American healthcare industry.

Martis Capital

Bain Capital Life Sciences specializes in buyouts, inflexion capital, growth capital, turnaround investments, and private equity. It invests in pharmaceutical, biotechnology, medical device, diagnostic, and life science tool companies across the globe, with a focus on companies that both drive medical innovation across the value chain and enable that innovation to improve the lives of patients with unmet medical needs. The differentiated skillset of the Bain Capital Life Sciences team enables it to deliver targeted capital and value-added strategic support to companies around critical phases of growth and inflexions in value.

Bain Capital Life Sciences

Hayfin was founded in 2009 with the ambition of creating one of Europe’s leading investment platforms. They focus on delivering best-in-class risk-adjusted returns for their investors across four strategies: Direct Lending, Special Opportunities, High-Yield Credit and Securitized Credit. Hayfin is a London based firm with offices in Amsterdam, Frankfurt, Mardid, Paris and Luxembourg. They consider their selves value investors, generating differentiated return through hard work, insightful analysis and disciplined investing. Hayfin seeks to recruit and retain exceptionally talented professionals. They believe in being local in each of their markets, and that their diverse mix of nationalities, cultures and languages makes them more connected to these markets. Most of their team are industry generalists, with their edge lying in their origination networks and proven expertise in managing complex restructurings, workouts and liquidations. That said, they employ dedicated, specialist teams in the areas of healthcare (life sciences), shipping (maritime) and real estate, where they believe their focused expertise provides an advantage. They operate across all major European geographies with offices in London, Paris, Madrid, Frankfurt, Luxembourg and Tel Aviv, and have a growing presence in the United States with an office in New York.

Hayfin Capital Management

Janus Henderson Investors focuses on investing performance and services. The firm connects institutional, retail, and high-net-worth clients with investment specialists who specialize in a variety of asset classes, such as equities, fixed income, real estate, and alternatives.

Janus Henderson Investors

HeartFlow

HeartFlow focuses on precision heart care, combining human ingenuity with technology. HeartFlow’s non-invasive HeartFlow FFRCT Analysis leverages artificial intelligence to create a personalized three-dimensional model of the heart. Clinicians can use this model to evaluate the impact a blockage has on blood flow and determine the best treatment for patients. HeartFlow’s technology is reflective of our Silicon Valley roots and incorporates over two decades of scientific evidence with the latest advances in artificial intelligence. The HeartFlow FFRCT Analysis is commercially available in the United States, UK, Canada, Europe, and Japan.

HeartFlow develops AI-powered, non-invasive precision heart care products for diagnosing and treating coronary artery disease (CAD). Its flagship product is the HeartFlow FFRCT Analysis, which creates a personalized 3D model of a patient's coronary arteries using data from a coronary CT scan. The model analyzes the impact of blockages on blood flow to the heart, providing physicians with detailed information to determine the severity of the patient's CAD and plan the appropriate treatment.

Pushing the envelope in MedTech with emerging technologies

Next-gen Medical Devices

HeartFlow Announces New Decision from Centers for Medicare & Medicaid Services Boosting CCTA Reimbursement and Access

HeartFlow develops AI-powered, non-invasive precision heart care products for diagnosing and treating coronary artery disease (CAD). Its flagship product is the HeartFlow FFRCT Analysis, which creates a personalized 3D model of a patient's coronary arteries using data from a coronary CT scan. The model analyzes the impact of blockages on blood flow to the heart, providing physicians with detailed information to determine the severity of the patient's CAD and plan the appropriate treatment.In addition to the FFRCT Analysis, HeartFlow offers the RoadMap Analysis, which helps identify stenoses in the coronary arteries, and the Plaque Analysis, which characterizes and quantifies coronary atherosclerosis. In October 2022, the FDA approved HeartFlow's RoadMap Analysis and Plaque Analysis.&nbsp;HeartFlow's products are designed to improve diagnostic accuracy, reduce unnecessary testing and procedures, and enhance clinical decision-making. The company's technology has been validated in over 500 peer-reviewed publications and used to diagnose and manage over 250,000 patients as of June 2024.&nbsp;Key customers and partnershipsThe company claims that, as of July 2024, over 80% of the top US heart hospitals had adopted its technology. As of January 2024, HeartFlow's products were available in over 1,000 hospital systems worldwide.&nbsp;In May 2021, HeartFlow partnered with MedAxiom to enhance cardiovascular care for coronary artery disease patients. In May 2024, it partnered with Banner Imaging to offer a new program for detecting coronary blockages using 3D modeling from imaging tests.&nbsp;

Convergent Dental, Inc. is a privately owned dental equipment and technology company. Its flagship product, Solea, is the only CO2 laser cleared by the FDA for all-tissue indications, delivering an anesthesia-free, blood-free, and suture-free experience for dentists and patients. Solea represents a breakthrough in dental laser technology, offering a distinct experience compared to traditional instruments or earlier laser treatments.
Solea is a novel 9.3-micron CO2 laser that nears the peak absorption of hydroxyapatite (enamel), enabling it to vaporize enamel with speed and precision. This unique wavelength, coupled with computer-controlled motors (galvos) that manipulate the beam thousands of times per second, allows dentists to perform procedures ranging from hard tissue to soft tissue with total control and efficiency.
A key feature of Solea is its variable-speed foot pedal, which lets dentists seamlessly transition from hard to soft tissue by adjusting the pressure applied. This intuitive design streamlines the learning curve for dentists accustomed to using a drill. Solea's three ergonomic handpieces – Contra-Angle, Straight, and Ultraguide – further enhance its versatility across various procedures.
Solea not only improves patient experiences but also offers practice benefits such as increased productivity, new patient flow, and efficiency gains. In October 2022, Convergent Dental received FDA clearance for Solea to aid in reducing mineral loss in dental enamel, protecting teeth against acid attack and caries development. This breakthrough application was commercially launched in November 2023 under the name Solea Protect.

Convergent Dental

Ossio is an orthopedic fixation technology company that has developed OSSIOfiber Intelligent Bone Regeneration Technology, a breakthrough implant material designed to securely fixate and fully integrate into the body's native anatomy without leaving any permanent hardware behind. This technology addresses the limitations of conventional metal and resorbable implants, combining unparalleled mechanical strength with natural bone healing.
Made from a proprietary mineral fiber matrix held together by a naturally degradable polymer, OSSIOfiber implants provide surgeons with a more biologically friendly way to restore patient stability and mobility. These implants are engineered to provide the strength required for functional fixation while allowing full integration into the native bone without adverse biological response.
Ossio's product portfolio includes compression screws, trimmable fixation nails, hammertoe fixation systems, suture anchors, and compression staples, all made with OSSIOfiber technology. These implants have received multiple FDA clearances since 2019, and the company has initiated commercialization of its products in the US. As of March 2022, over 6,000 implantations of OSSIOfiber products had been performed, demonstrating adoption of this innovative technology.
OSSIOfiber Intelligent Bone Regeneration Technology can address various surgical applications through the manufacturing of implant designs like nails, screws, staples, anchors, and plates. Ossio plans to pursue multiple applications in distal extremities, trauma, sports, reconstruction, pediatrics, and spine segments.
In February 2023, Ossio launched the world's first and only non-permanent compression staple made with OSSIOfiber technology, designed for predictable bone in-growth, regeneration, and replacement.

Ossio

Casana is a healthcare technology company that has developed the Heart Seat, an innovative toilet seat that enables effortless, integrated, and consistent in-home health monitoring. The Heart Seat is a replacement for a standard toilet seat and is designed to measure key clinical parameters such as heart rate, blood oxygen saturation (SpO2), and blood pressure.
In May 2023, Casana received FDA clearance for the Heart Seat to measure heart rate and SpO2 in adults aged 22 years and older, weighing between 90 to 350 pounds. The company plans to file for additional indications, including systolic and diastolic blood pressure, with the goal of launching the product in the market by the end of 2023.
The Heart Seat is equipped with sensors that passively capture health data whenever the seat is used, eliminating the need for user compliance or behavior changes. The data is automatically uploaded to the Casana Cloud, where it can be viewed by healthcare providers, enabling them to monitor patients' health trends and respond to changes in near real-time.
Casana's technology allows for the effortless collection of consistent and reliable data, assisting medical teams in monitoring chronic conditions beyond the hospital or physician's office. The company aims to unlock a new category in healthcare technologies that enables seamless, integrated, and continuous in-home health monitoring.
In January 2022, Casana was acquired by an undisclosed entity, further accelerating the commercialization of the Heart Seat.

Casana

Neurent Medical is a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, particularly chronic rhinitis. The company's flagship product is the NEUROMARK System, a device that received US Food and Drug Administration (FDA) 510(k) clearance in October 2021.
The NEUROMARK System is designed to gently apply controlled low-power radio frequency (RF) energy to target regions of the nasal cavity, disrupting the parasympathetic nerve signals that can trigger an inflammatory response. This alleviates chronic rhinitis symptoms such as persistent congestion, rhinorrhea (runny nose), swelling of the mucosal membrane, sneezing, and nasal itching. The system's unique flexible leaflet design and proprietary smart algorithms enable precise neurolysis (disruption) of the posterior nasal nerves (PNN) and accessory pathways, accommodating a range of patient anatomies while maintaining mucosal and vascular integrity.
Neurent Medical announced the limited market release of the NEUROMARK System in the US in February 2023, following the establishment of a new Category I Current Procedural Terminology (CPT) code by the American Medical Association (AMA) for PNN procedures, effective January 2024. The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) also endorsed the PNN procedure in 2023.

Neurent Medical

Genetesis is a medical imaging company specializing in biomagnetic cardiac imaging solutions. It has developed CardioFlux, a flagship magnetocardiography (MCG) system that non-invasively identifies myocardial ischemia, a condition where blood flow to the heart muscle is reduced. The technology measures the magnetic fields generated by the heart's electrical activity to detect ischemia within minutes, without using pharmaceuticals or radiation. CardioFlux MCG is designed to provide advanced imaging while prioritizing patient comfort.
The company's solutions target the diagnosis of coronary microvascular disease (CMD), a condition that has been challenging to identify due to a lack of effective functional diagnostics. By offering an accurate and rapid test for CMD, Genetesis aims to address an unmet clinical need and enable timely management of the condition.
In April 2023, the US Food and Drug Administration (FDA) granted CardioFlux MCG Breakthrough Device designation for the non-invasive diagnosis of myocardial ischemia in patients suspected of having CMD.
Genetesis was founded in 2013 and is headquartered in Mason, Ohio. The company has received over USD 40 million in funding to date, including a USD 17.5 million Series C round in October 2022. In April 2020, TDK Ventures, the corporate venture capital arm of TDK Corporation, invested in Genetesis, providing access to TDK's expertise in areas like biomagnetic sensors and magnetic noise suppression.

Genetesis

Companies that develop diagnostic devices used in a hospital setting to identify a disease, condition, or injury, such as imaging systems and endoscopes

Companies that develop implantable medical devices designed to be surgically placed inside the human body, either temporarily or permanently, including devices such as pacemakers, artificial joints, stents, and cochlear implants

Companies that develop non-surgical devices that are used in a procedure or intervention to cure or relieve a patient from an illness or disease such as laser treatments, dental equipment, and wound care management

Companies that develop monitoring devices that are used in a hospital setting to measure patient vital signs and ensure patient well-being post-treatment, such as cardiac and respiratory monitoring systems

Providers of software that enhances the functionality of medical device hardware (diagnosis, treatment, and monitoring)

Companies that develop surgical devices involving invasive interventions (cutting into a patient's body tissues) to treat, cure, or relieve a patient of an illness or disease

Companies that develop devices to administer pharmaceutical substances into a patient's body, ensuring controlled release or targeted delivery, specifically for use in clinical settings to treat or manage medical conditions effectively

Providers of software that helps manage risks, ensure quality, and streamline audit processes during medical device development

IoT connects devices to EHR systems for precise patient diagnosis and treatment support

Devices are linked to software platforms that use digital technologies such as AI/ML and VR

Startups leverage AI/ML and deep learning to support patient diagnosis and early detection

HeartFlow

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless